Detail akcie SOPHiA GENETICS Rg online

Business Summary: SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Sophia Genetics SA revenues increased 17% to $55.6M. Net loss increased 26% to $59.8M. Revenues reflect Rest of EMEA segment increase of 33% to $17.9M, United States segment increase of 12% to $7.8M, Italy segment increase of 11% to $7.8M. Higher net loss reflects Advanced Medical Equipment & Technology segment loss increase of 7% to $52.4M.